BioArctic launches Leqembi Iqlik for initiation treatment in the US (SEK 335.40, -0.20)
Eisai reports Q1 net income attributable ¥18.24B vs FactSet ¥16.71B [4 est, ¥11.50-20.70B]
Eisai reports Q1 global revenue of LEQEMBI ¥29.30B vs year-ago ¥23.10B
Powered by FactSet Research Systems Inc.